Publication:
Predicting Recurrent Venous Thromboembolism in Patients With Deep-Vein Thrombosis: Development and Internal Validation of a Potential New Prediction Model (Continu-8).

cris.virtualsource.author-orcidcc26e72f-f835-470f-a4c4-64b2ea3f2eb2
datacite.rightsopen.access
dc.contributor.authorNagler, Michael
dc.contributor.authorVan Kuijk, Sander M J
dc.contributor.authorTen Cate, Hugo
dc.contributor.authorPrins, Martin H
dc.contributor.authorTen Cate-Hoek, Arina J
dc.date.accessioned2024-09-02T17:41:11Z
dc.date.available2024-09-02T17:41:11Z
dc.date.issued2021
dc.description.abstractBackground: Previous prediction models for recurrent thromboembolism (VTE) are often complicated to apply and have not been implemented widely. Aim: To develop and internally validate a potential new prediction model for recurrent VTE that can be used without stopping anticoagulant treatment for D-dimer measurements in patients with provoked and unprovoked DVT. Methods: Cohort data of 479 patients treated in a clinical care pathway at Maastricht University Medical Center were used. Predictors for the Cox proportional hazards model (unprovoked DVT, male gender, factor VIII levels) were derived from literature and using forward selection procedure. The scoring rule was internally validated using bootstrapping techniques and the predictive ability was compared to existing prediction models. Results: Patients were followed for a median of 3.12 years after stopping anticoagulation treatment (IQR 0.78, 3.90). Sixty-four of 479 patients developed recurrent VTE (13%). The scoring rule consisted of unprovoked DVT (yes: 2 points), male sex (yes: 1 point), and factor VIII > 213 % (yes: 2 points) and was categorized into three groups [i.e., low risk (score 0), medium risk (scores 1, 2, or 3) and high risk (scores 4 and 5)]. The concordance statistic was 0.68 (95% CI: 0.61, 0.75). Conclusion: The discriminative ability of the new Continu-8 score was adequate. Future studies shall verify this score in an independent setting without stopping anticoagulation treatment.
dc.description.sponsorshipUniversitätsinstitut für Klinische Chemie (UKC)
dc.identifier.doi10.48350/157848
dc.identifier.pmid33889600
dc.identifier.publisherDOI10.3389/fcvm.2021.655226
dc.identifier.urihttps://boris-portal.unibe.ch/handle/20.500.12422/42842
dc.language.isoen
dc.publisherFrontiers
dc.relation.ispartofFrontiers in cardiovascular medicine
dc.relation.issn2297-055X
dc.relation.organizationDCD5A442BA49E17DE0405C82790C4DE2
dc.subjectclinical decision making health services research risk factors venous thrombosis/epidemiology venous thrombosis/mortality venous thrombosis/therapy
dc.subject.ddc600 - Technology::610 - Medicine & health
dc.titlePredicting Recurrent Venous Thromboembolism in Patients With Deep-Vein Thrombosis: Development and Internal Validation of a Potential New Prediction Model (Continu-8).
dc.typearticle
dspace.entity.typePublication
oaire.citation.startPage655226
oaire.citation.volume8
oairecerif.author.affiliationUniversitätsinstitut für Klinische Chemie (UKC)
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.date.licenseChanged2021-08-13 14:06:20
unibe.description.ispublishedpub
unibe.eprints.legacyId157848
unibe.refereedtrue
unibe.subtype.articlejournal

Files

Original bundle
Now showing 1 - 1 of 1
Name:
2021_Front_Cardiovasc_Med_Nagler.pdf
Size:
911.41 KB
Format:
Adobe Portable Document Format
License:
https://creativecommons.org/licenses/by/4.0
Content:
published

Collections